yubM Antibody

What are the primary methods used for discovering novel antibodies?

Modern antibody discovery employs several complementary approaches, each with distinct advantages:

• Hybridoma technology: Involves fusion of antibody-producing B cells with myeloma cells to create immortalized cell lines that secrete monoclonal antibodies. This approach works well for many targets but has limitations in producing fully human antibodies .

• Phage display libraries: Enables in vitro selection on target molecules by displaying antibody fragments on bacteriophage surfaces. This method allows screening of diverse antibody repertoires (up to 10^11 variants) covering all human germlines .

• Single B-cell approaches: Isolates antigen-specific B cells from which antibody genes are cloned and expressed. This preserves natural heavy and light chain pairings that evolved during immune responses .

• Antibody-secreting cell (ASC) technologies: Focuses on cells actively producing antibodies during immune responses. This approach has advantages over traditional methods because it increases the likelihood of identifying functional antibodies with potency .

• AI-assisted design: Emerging computational methods that design antibodies in silico, reducing the need for extensive physical screening .

The selection of method depends on the specific research goals, target complexity, and desired antibody properties.

How does the antibody discovery pipeline function from target identification to lead optimization?

The typical antibody discovery pipeline follows a systematic progression through multiple stages. YUMAB's "3 Steps fast track" exemplifies this process:

Step 1: Hit Discovery

• Begin with library selection against the target of interest

• Libraries can be naïve human libraries or custom-made from patients/immunized animals

• Within weeks, identify antibody hits specific to targets with broad epitope coverage

• Complete initial binding assays to confirm target engagement

Step 2: Lead Engineering

• Optimize clinically relevant parameters (affinity, stability, specificity)

• Apply AI-assisted rational mutagenesis combined with in-vitro evolution

• Increase the diversity of potential candidates with improved features

Step 3: Lead Development

• Comprehensive characterization of final lead candidates

• Evaluate expression, stability, binding kinetics, and functional properties

• Select candidates with optimal developability profile

This streamlined approach allows researchers to progress systematically from target to lead candidates with predefined properties and maximum developability.

What characteristics differentiate successful antibody candidates during early screening phases?

Successful antibody candidates exhibit several key characteristics that researchers should evaluate during early screening:

• Target specificity: Selective binding to the intended target with minimal cross-reactivity

• Binding affinity: Strong binding kinetics with appropriate on/off rates

• Epitope diversity: Recognition of diverse epitopes on the target, particularly functionally relevant regions

• Stability: Thermodynamic and colloidal stability under physiological conditions

• Developability: Absence of sequence liabilities that could impact manufacturing or in vivo performance

• Functional activity: Demonstration of the desired biological effect (e.g., neutralization, receptor blocking)

Early screening should incorporate assays that assess these parameters to identify the most promising candidates. For example, YUMAB's discovery process includes "careful in vitro selection, high throughput screening and comprehensive validation" to deliver antibody leads with "pre-designed properties and maximum developability" .

How does zero-shot AI technology advance antibody discovery for undrugged targets?

Zero-shot AI technology represents a significant advancement for discovering antibodies against challenging targets such as G protein-coupled receptors (GPCRs) and ion channels. This approach works by:

• De novo sequence design: Generating antibody sequences based solely on antigen sequences and/or target structures without requiring initial physical screening

• Overcoming conventional limitations: Addressing challenges where traditional methods fail because target proteins cannot be expressed or maintained in pathophysiological conformations

• Expanding target space: Enabling discovery against traditionally "undruggable" targets

• Increasing sequence diversity: Generating a broader range of antibody sequences for each target

The collaboration between YUMAB and MOLCURE exemplifies this approach, combining "MOLCURE's decade of experience in AI-design of antibodies with over a billion proprietary experimental data points" and "YUMAB's thirty years of technical excellence in antibody discovery, engineering and manufacturing" .

This technology is particularly valuable for therapeutic targets where conventional screening methods have historically failed, potentially opening new avenues for drug development against previously inaccessible disease targets.

What methodologies enable the generation of human recombinant monoclonal antibodies directly from single cells?

Generating human recombinant monoclonal antibodies from single cells involves several specialized techniques:

• Single-cell isolation: Antigen-specific B cells or antibody-secreting cells (ASCs) are isolated using flow cytometry or microfluidic systems

• Rapid cloning: Heavy and light chain variable region genes are amplified directly from single cells via RT-PCR

• Expression vector construction: Antibody genes are cloned into expression vectors containing appropriate constant regions

• Transient expression: Recombinant antibodies are produced in mammalian expression systems (typically HEK293 cells)

• Functional screening: Antibodies are characterized for binding, specificity, and functional properties

A rapid workflow described in one study allows "obtaining human recombinant monoclonal antibodies directly from single antigen-specific antibody secreting cells." This approach has distinct advantages over traditional methods because it preserves the natural pairing of heavy and light chains that evolved during immune responses .

The method demonstrated success in generating SARS-CoV-2 neutralizing antibodies, with testing showing activity against the original Wuhan strain as well as Delta and Omicron variants. The neutralizing activity was tested by serially diluting immunoglobulins starting at 10 μg/mL and assessing virus neutralization in Vero cells .

How do researchers analyze antibody-antigen mutations to understand binding disruption?

Understanding how antigen mutations affect antibody binding is critical for therapeutic antibody development, especially in rapidly evolving pathogens. Researchers utilize sophisticated approaches:

• Comprehensive mutation analysis: Every possible antigen point mutation in the antibody-protein interface is assessed using computational methods such as Rosetta molecular mechanics force field

• Hotspot identification: Critical residues that contribute disproportionately to binding energy are identified

• Indirect effects evaluation: Analysis of how mutations can disrupt binding through conformational changes rather than direct contact disruption

• Energy contribution quantification: Assessment of attractive versus repulsive energies in binding interactions

One comprehensive study analyzed "every possible antigen point mutation in the interface of 246 antibody-protein complexes" to understand "how antigen mutations affect antibody binding." This research revealed "the effects of mutating critical hotspot residues versus other positions, how many mutations are necessary to be likely to disrupt binding, the prevalence of indirect effects of mutations on binding, and the relative importance of changing attractive versus repulsive energies" .

These insights guide antibody repurposing efforts, which involve modifying existing antibodies to recognize mutated antigens—an approach that proved valuable during the COVID-19 pandemic.

What experimental design considerations are crucial when evaluating neutralizing antibodies?

Designing robust experiments to evaluate neutralizing antibodies requires careful consideration of multiple factors:

• Target representation: Include both wild-type and variant forms of the target to assess breadth of neutralization

• Concentration range: Test antibodies across a wide concentration range (typically starting at 10 μg/mL with serial dilutions) to determine IC50 values

• Appropriate cell models: Select cell lines that express relevant receptors and support pathogen replication

• Controls: Include positive control antibodies with known neutralization properties and negative controls

• Complementary assays: Combine binding assays (ELISA, BLI, SPR) with functional neutralization tests

• In vivo validation: Follow in vitro studies with animal models when possible to confirm protective efficacy

For example, one study tested monoclonal antibodies against "the original SARS-CoV-2 virus from Wuhan, as well as its Delta and Omicron variants" by serially diluting antibodies and testing virus neutralization on Vero cells .

Another study evaluating an anti-malarial human monoclonal antibody demonstrated the importance of comprehensive testing, where the antibody "L9 was more potent than six published neutralizing human PfCSP mAbs at mediating protection against mosquito bite challenge in mice." The researchers employed "isothermal titration calorimetry and multiphoton microscopy" to characterize binding properties and mechanism of action .

How should researchers optimize antibody screening protocols to identify rare broadly reacting antibodies?

Identifying rare broadly reacting antibodies that can target multiple variants or even different pathogens requires specialized screening approaches:

• Advanced B-cell isolation: Implement techniques to isolate B cells that bind to multiple antigens simultaneously

• Sequential screening: Screen first for binding to conserved targets, then assess cross-reactivity to variants

• Deep sequencing: Apply next-generation sequencing to identify unusual antibody sequences with high somatic hypermutation

• Structure-guided selection: Focus on antibodies targeting highly conserved structural elements

• Novel technical platforms: Utilize technologies like LIBRA-seq (Linking B-cell Receptor to Antigen Specificity through sequencing) to match antibody sequences to their antigen specificity

Researchers at Vanderbilt University Medical Center developed a method to "isolate and amplify a class of rare antibodies that can target a wide range of different viruses." Their discovery, reported in PLOS Pathogens, "could help open the door to the development of effective vaccines and antibody therapies with an 'exceptional breadth of pathogen coverage.'"

This approach overcomes the challenge that "looking for such rare antibody phenotypes is exceptionally challenging" by using LIBRA-seq technology, which "enables researchers to map the unique sequence of amino acids that make up the reactive portion of an antibody and match it to the specificity for multiple antigens simultaneously" .

What methods are most effective for characterizing bispecific antibodies and assessing their dual-targeting capabilities?

Characterizing bispecific antibodies requires specialized approaches to evaluate their unique dual-targeting capabilities:

• Simultaneous binding assays: Assess binding to both targets concurrently using techniques like sandwich ELISA or biolayer interferometry

• Cell-based functional assays: Test biological activity that depends on simultaneous engagement of both targets

• Structural analysis: Utilize techniques like cryo-EM to visualize the structural arrangement of binding domains

• Linker optimization: Evaluate different linker compositions and lengths to ensure proper spacing and display of antigen-binding domains

• Chain pairing validation: Implement analytical methods to confirm correct assembly of the intended bispecific structure

The design of bispecific antibodies presents unique challenges, as "the added complexity requires judicious design considerations as well as extensive molecular engineering to ensure formation of high quality bsAbs with the intended mode of action" .

Key considerations include "decreased biophysical stability from fusion of exogenous antigen-binding domains to antibody chain mispairing leading to formation of antibody-related impurities that are very difficult to remove" .

Researchers must carefully select appropriate formats and engineering strategies to overcome these challenges while maintaining the desired dual-binding functionality.

How do antibody discovery approaches differ when targeting membrane proteins versus soluble antigens?

Targeting membrane proteins requires specialized approaches compared to soluble antigens:

Antibody-secreting cells (ASCs) offer particular advantages for membrane protein targeting as "soluble antibodies secreted by ASCs are suitable for screening both soluble and membrane-bound antigens, and the development of antibodies against structurally-complex transmembrane proteins is highly desirable" .

This advantage contrasts with membrane-bound antibodies on memory B cells, which are "only suitable for screening mAbs against soluble antigens unless sophisticated engineering techniques are employed, making the screening of memory B cells for membrane-bound antigens technically challenging" .

What approaches are most effective for evaluating antibodies against rapidly mutating targets like viruses?

Evaluating antibodies against rapidly mutating targets requires comprehensive strategies:

• Variant panels: Test antibodies against panels of natural variants and engineered mutants covering key mutations

• Epitope binning: Group antibodies by epitope to identify those targeting conserved regions

• Escape mutation mapping: Identify mutations that allow the target to escape antibody binding

• Structural analysis: Determine antibody-antigen complex structures to understand the molecular basis of broad neutralization

• Combination testing: Evaluate antibody cocktails targeting non-overlapping epitopes to prevent escape

• Active learning approaches: Implement computational methods to efficiently predict binding to new variants

Recent research demonstrates the value of active learning for "improving out-of-distribution lab-in-the-loop antibody-antigen binding prediction." This study evaluated "fourteen novel active learning strategies for antibody-antigen binding prediction" and found that "three of the fourteen algorithms tested significantly outperformed the baseline where random data are iteratively labeled." The best algorithm "reduced the number of required antigen mutant variants by up to 35%, and sped up the learning process by 28 steps compared to the random baseline" .

Such approaches enable more efficient experimental design when studying antibody binding to rapidly evolving targets.

How can researchers determine if host immunity facilitates or impedes therapeutic antibody efficacy?

Understanding the complex interplay between host immunity and therapeutic antibodies requires careful investigation:

• Serum competition assays: Determine if host antibodies compete with therapeutic antibodies for epitope binding

• Fc receptor engagement analysis: Assess how host immune factors affect antibody effector functions

• Immune complex formation studies: Evaluate if therapeutic antibodies form complexes with host factors

• Longitudinal monitoring: Track changes in host immunity and therapeutic antibody efficacy over time

• Resistance emergence tracking: Monitor development of escape mutations under antibody pressure

A prospective, observational cohort study demonstrated how "host immunological responses facilitate development of SARS-CoV-2 Spike mutations under therapeutic monoclonal antibody pressure" . The study followed COVID-19 patients receiving various monoclonal antibody treatments over 28 days, monitoring "viral loads, de novo Spike mutations, mAb kinetics, seroneutralization against infecting variants of concern, and T cell immunity" .

The researchers observed that therapeutic antibody levels remained high throughout the study period, with "average anti-RBD and anti-S titers on D28 remained at 5.8 and 2.9 million BAU/mL, respectively" . This type of comprehensive monitoring helps understand how host immunity interacts with therapeutic antibodies and potentially contributes to treatment resistance.

How is active learning being applied to improve antibody-antigen binding prediction?

Active learning represents an emerging approach to efficiently predict antibody-antigen interactions:

• Iterative data generation: Starting with a small labeled dataset and strategically expanding it based on model uncertainty

• Library-on-library approaches: Evaluating many-to-many relationships between antibodies and antigens

• Out-of-distribution prediction: Addressing the challenge of predicting interactions for antibodies and antigens not represented in training data

• Cost reduction: Minimizing the number of experiments needed to achieve accurate predictions

Recent research developed "fourteen novel active learning strategies for antibody-antigen binding prediction in a library-on-library setting" and evaluated their performance using the Absolut! simulation framework. The best algorithms "significantly outperformed the baseline where random data are iteratively labeled," reducing "the number of required antigen mutant variants by up to 35%" and speeding up "the learning process by 28 steps compared to the random baseline" .

This approach is particularly valuable because "generating experimental binding data is costly, limiting the availability of comprehensive datasets." Active learning helps overcome this limitation by strategically selecting the most informative experiments to perform.

What advantages do VHH antibodies (nanobodies) offer for research applications compared to conventional antibodies?

VHH antibodies (nanobodies) provide several distinct advantages for research applications:

• Size: With a molecular weight approximately one-tenth that of conventional antibodies (~15 kDa vs. ~150 kDa), they can access restricted spaces and epitopes14

• Structural simplicity: They lack light chains and glycan modifications while maintaining full antigen binding capacity14

• Stability: Generally more thermostable than conventional antibodies

• Production: Can be expressed in bacterial systems, making them more economical to produce

• Penetration: Better tissue penetration and ability to reach sterically hindered targets

• Modularity: Easily engineered into multivalent or multispecific formats

The structural characteristics of nanobodies enable them to bind epitopes that might be inaccessible to conventional antibodies. As described in one presentation, "the perotropes on nanobodies take up a large component of the molecule" and their small size allows them to "get into places where perhaps steric difficulties with monoclonal antibodies prevent" access14.

These properties make VHH antibodies particularly valuable for research applications requiring access to challenging epitopes or constrained environments.

How are companies implementing collaborative approaches to accelerate antibody discovery and optimization?

Strategic collaborations are increasingly important in advancing antibody discovery and optimization:

• Complementary expertise integration: Combining different technological strengths and capabilities

• Platform technology sharing: Accessing specialized technologies through partnerships

• Data integration: Leveraging diverse datasets to improve predictive capabilities

• Multi-disciplinary teams: Bringing together experts in different aspects of antibody research

The collaboration between Ymmunobio AG and YUMAB GmbH exemplifies this approach. Ymmunobio, "a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments," partnered with YUMAB to "complement its antibody development by utilizing YUMAB's expertise and platform for optimizing its antibodies" .

Similarly, YUMAB and MOLCURE's collaboration combines "MOLCURE's decade of experience in AI-design of antibodies" with "YUMAB's thirty years of technical excellence in antibody discovery, engineering and manufacturing" to advance "zero-shot AI technology for antibody discovery" targeting challenging protein classes like GPCRs and ion channels .

These collaborative approaches accelerate innovation by combining complementary strengths and resources to address complex challenges in antibody discovery and optimization.